Results 41 to 50 of about 5,242 (246)
Institute for Quality and Efficiency in Health Care: Germany [PDF]
, 2009 Provides an overview of evidence-based policy making in the German healthcare system. Focuses on the Institute for Quality and Efficiency in Health Care, which evaluates comparative effectiveness of drugs and medical services for decisions on ...
Mona Nasser, Peter Sawicki
core
Höchstmöglicher ESMO-Wert vs. kein Zusatzznutzen
Monitor VersorgungsforschungIm Titelinterview mit „Monitor Versorgungsforschung“ (02/25) ging Dr. med. Thomas Kaiser, Institutsleiter des IQWiG, kurz auf die Nutzenbewertung des Wirkstoffs Pembrolizumab und des MSD-Arznemittels „Keytruda“ ein (1): Auf die Frage „Wie kommt es, dass ...
Peter Stegmaier
doaj +1 more source
Systematic Reviews, 2018 Background Previous research shows that many authors of Cochrane overviews were also involved in some of the included systematic reviews (SRs). This type of dual (co-)authorship (DCA) may be a conflict of interest and a potential source of bias.
Dawid Pieper +3 more
doaj +1 more source
Trials, 2021 Background Tonsillectomy is one of the most frequently performed surgeries in children and young adults worldwide. For decades, tonsillectomy was the surgical treatment of choice for recurrent acute tonsillitis. Tonsillotomy was used in some countries as
Orlando Guntinas-Lichius +4 more
doaj +1 more source
Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward [PDF]
, 2016 List of regulatory documents organized per country and list of publications.
Alexandra Nolting +4 more
core +7 more sources
Patient Preference and Adherence, 2018 Background and purpose The German Institute for Quality and Efficiency in Health Care (IQWiG) previously tested two preference elicitation methods in pilot projects and regarded them as generally feasible for prioritizing outcome-specific results of ...
Vera Vennedey +9 more
semanticscholar +1 more source
Cancer, Volume 132, Issue 3, 1 February 2026.Abstract Background Event‐free survival (EFS) and complete response rate (CRR) are recommended as primary endpoints in bladder cancer trials to enable timely assessment of therapeutic benefit. However, their surrogacy relationship with overall survival (OS) in high‐risk non–muscle‐invasive bladder cancer (HR NMIBC) remains unclear.
Rituparna Bhattacharya +8 more
wiley +1 more source
GMS Medizinische Informatik, Biometrie und EpidemiologieFor newly authorised medicinal products with new active substances, a benefit assessment is carried out at the time of their market access in Germany. The subject of this assessment is the question of the additional benefit of the new active substance ...
Kaiser, Thomas, Vervölgy, Volker
doaj +1 more source
Cost recommendation under uncertainty in IQWiG’s efficiency frontier framework [PDF]
, 2016 Background: The National Institute for Quality and Efficiency in Health Care (IQWiG) employs an efficiency frontier (EF) framework to facilitate setting maximum reimbursable prices for new interventions.
Al, Maiwenn J. +3 more
core +2 more sources
Cost‐Effectiveness Analysis of Risky Health Interventions: Moving Beyond Risk Neutrality
Ratio, Volume 38, Issue 4, Page 219-227, December 2025.ABSTRACT Cost‐effectiveness analysis for health interventions is traditionally conducted in a risk‐neutral way, insensitive to risk attitudes in the population, which are potentially non‐neutral. While the standard outcome metric of quality‐adjusted life years (QALYs) aims to be deferential to people's valuations of health states, cost‐effectiveness ...
Johanna Thoma
wiley +1 more source